Detail
| LncRNA Name | H19 |
| Synonyms | H19, ASM, ASM1, BWS, D11S813E, LINC00008, NCRNA00008, WT2 |
| Region | GRCh38_11:1995176-2001470 Sequence |
| Ensembl | ENSG00000130600 |
| RefSeq | NR_002196 |
| Circulating | ✘ |
| Drug-resisitant | ✘ |
| Prognostic | ✔ |
| MiRNA | ✔ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | glioma |
| ICD-0-3 | M9380/3 |
| Methods | qPCR, RNAi, Cell proliferation assay etc. |
| Sample | glioma tissues, cell lines (U251 and U87) |
| Expression Pattern | up-regulated |
| Function Description | LncRNA H19 was overexpressed in glioma tissue and cell lines. In tissue, higher expression levels were observed in more advanced stages of the tumor. Furthermore, lncRNA H19 was negatively associated with patient survival time. In cell culture experiments, silencing of lncRNA H19 diminished proliferation of glioma cell lines. These effects of lncRNA H19 appeared to be intermediated by miR-675. |
| Pubmed ID | 27981546 |
| Year | 2016 |
| Title | LncRNA H19 is overexpressed in glioma tissue, is negatively associated with patient survival, and promotes tumor growth through its derivative miR-675. |
| External Links |
| Links for H19 | GenBank HGNC lncrnadb Noncode |
| Links for glioma | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.